DiaMedica Therapeutics Inc. - Common Stock (DMAC)

DiaMedica Therapeutics (NASDAQ:DMAC) said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the company reported a cash runway it expects to extend through 2027. President and Chief Executive Offi

DiaMedica (DMAC) Q4 2025 Earnings Transcript

DiaMedica (DMAC) Q1 2026 Earnings Transcript

DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday.

DiaMedica reports Q3 2025 results, advancing DM199 for stroke and preeclampsia. The company has a cash runway into H2 2027 to fund clinical trials.

DiaMedica Therapeutics reports Q2 2025 results with a narrower-than-expected loss, positive clinical updates, and strong cash position. Stock surges 19% post-earnings.

DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

DMAC stock results show that DiaMedica Therapeutics met analyst estimates for earnings per share the fourth quarter of 2023.